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Summary Expenrmental studies have been carried out using 5-aminolaevulinic acid (ALA) to induce transient
porphyrin photosensitisation for photodynamic therapy (PDT) in a pancreatic cancer model in Syrian golden
hamsters. ALA was given either intravenously or orally (in bolus or fractionated doses) with the laser light
delivered by means of a bare fibre touching the tissue surface or external irradiation using a light-integrating
cylindrical applicator. Animals were killed 1-24 h after ALA administration for pharnacokinetic studies and
3-7 days after light exposure to study PDT-induced necrosis. A separate survival study was also performed
after a fractionated oral dose of ALA and external irradiation. Protoporphyrin IX sensitisation in the tumour
tissue as measured by quantitative fluorescence microscopy was highest after intravenous administration of
200 mg kg-' ALA and then in decreasing order after oral fractionated and oral bolus doses (both
400 mg kg-'). Laser light application at 630 nm to give 12-50 J from the bare fibre or 50 J cm- 2 using surface
illumination with the cylindrical applicator resulted in tumour necrosis up to 8 mm in depth. In larger tumours
a rim of viable tumour was observed on the side opposite to illumination. In a randomised study, survival of
treated animals was significantly longer than in the untreated control group (log-rank- test, P<0.02), although
all animals died of recurrent tumour. This technique shows promise in the treatment of small volumes of
tumour in the pancreas.
Pancreatic cancer has one of the poorest prognoses of any
cancer. Most patients die within 6 months of diagnosis. The
1 and 5 year survival rates are about 10% and 1-2% respec-
tively. It is one of the most common cancers of the gast-
rointestinal tract, and its incidence is increasing. Radical
surgery is rarely possible, and radiotherapy and chemo-
therapy are of no proven benefit. Photodynamic therapy
(PDT) is a new and promising approach to therapy for
tumours. It is a non-thermal technique for producing
localised tissue necrosis with light-activated photosensitising
compounds. Systemic administration of the photosensitiser is
followed by exposure to laser light at a wavelength matched
to an absorption peak of the sensitiser, resulting in the
generation of cytotoxic singlet oxygen. Ideally, the photosen-
sitiser should be selectively retained in the tumour and not in
the surrounding normal tissue. This would ensure safe dest-
ruction of the tumour within normal areas. However, even if
there is some selectivity in the tumour uptake of the
photosensitiser, truly selective destruction is difficult to
obtain and therefore some degree of normal tissue damage
has to be accepted provided safe healing can occur (Bown,
1990). Haematoporphyrin derivative (HpD) and its purer
commercial variants (e.g. Photofrin) are the most commonly
used photosensitisers in clinical practice. They are both
rather poorly defined mixtures of porphyrins and have the
clinically important disadvantage of causing prolonged skin
photosensitivity lasting for about 4-6 weeks (Dougherty et
al., 1990).
Pancreatic cancer has never been treated by PDT in
humans, but experim6ntal studies on pancreatic tumour
models in hamsters or rats have been carried out (Mang &
Wieman, 1987; Schroder et al., 1988; Chatlani et al., 1992).
The common conclusions drawn from those studies are
encouraging. Necrosis of the pancreatic cancer was achieved
easily and, more importantly, normal pancreatic tissue sur-
rounding the tumour showed resistance to PDT damage
(Mang & Wieman, 1987; Nuutinen et al., 1991; Chatlani et
al., 1992). Photofrin or aluminium sulphonated
phthalocyanine (AlSPc) was used as the photosensitiser in
these studies. AlSPc has better characteristics than Photof-
rin, causing much less severe and less prolonged skin
photosensitivity (Tralau et al., 1989), but its clinical use is
not yet approved. Another particularly promising approach
is the use of 5-aminolaevulinic acid (ALA), and recently this
means of photosensitisation has been studied intensively.
ALA is a naturally occurrng precursor in the biosynthetic
chain for haem production. The last step, which is rate
limiting, involves conversion of the photosensitising species
protoporphyrin IX (PPIX) to haem. Upon exogenous
administration ALA may be quickly metabolised to PPIX,
which then accumulates in the tissues with consequent
endogenous photosensitisation that can be exploited for PDT
(Malik & Lugaci, 1987; Divaris et al., 1990). Favourable
results have been obtained in the treatment ofanimal tumour
models (Bedwell et al., 1992; Peng et al., 1992) and also after
topical application of ALA for 300 cutaneous basal cell
carcinoma lesions in Canada (Kennedy & Pottier, 1992) and
in oral cancer patients following systemic ALA administra-
tion (Grant et al., 1993). The main advantages of using ALA
as a photosensitising agent lie in the rapid elimination of
ALA from the body, short-lived photosensitisation lasting
not longer than 24 h and the possibility of oral administra-
tion, which is more acceptable and easier than any parenteral
route (Berlin et al., 1956; Mustajoki et al., 1992; Grant et al.,
1993; Loh et al., 1993a). ALA-induced PPIX sensitisation has
not been studied previously in experimental pancreatic
cancer. Additionally, none of the aforementioned studies
with Photofrin or AlSPc sensitisation in pancreatic tumour
models explored whether PDT could improve the survival of
treated animals.
The aim of this study was to investigate the possibility of
using ALA-induced PPIX for PDT for a transplanted panc-
reatic cancer in the Syrian golden hamster. We studied PPIX
sensitisation kinetics and laser irradiation effects in the panc-
reatic tumour and normal pancreas after intravenous and
oral administration of ALA. Additionally, in a separate
study, the survival time after PDT was compared with a
control, non-treated group of tumour-bearing animals.
Materials and methods
Tumour model
Female Syrian golden hamsters weighing 80-120 g were used
in all experiments. Laparotomies were performed under int-
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raperitoneal injection of xylainme 10 mgkg-' and ketamine
200 mgkg-', which provided good general anaesthesia. A
pancreatic tumour was established at laparotomy by int-
rapancreatic (into the gastric lobe) injection of 10' cells from
the pancreatic cancer line (PC-1), which was obtained from
The Eppley Institute for Research in Cancer and Allied
Diseases, Univerity of Nebraska Medical Centre, Omaha,
USA. The PC-1 line has been described in detail elsewhere
(Egami et al., 1989) and was derived from a hamster panc-
reatic cancer induced by N-nitrosobis(2-oxopropyl)amine
(BOP). This model retains the histological, biological and
antigenic properties of the primary ductal carcinoma and is
very similar to human disease (Takiyama et al., 1990). The
cell culture medium consisted of RPMI-1640 supplemented
with penicillin G (5,000 IU ml-'), streptomycin
(5.000 tgml-') (all from Flow Laboratonres, Irvine, UK),
10% fetal calf serum (Advanced Protein products, UK) and
L-glutamine 200 mM solution (Sigma, UK). For intrapanc-
reatic injection, cultured cells were detached from the bottom
of plastic culture flasks by 0.05% trypsin and 0.02% EDTA
solution (Boehringer Mannheim, Germany) and were
suspended in 0.2-0.3 ml of normal saline. Three weeks after
the injection, pancreatic tumour could be detected in the
gastric lobe of the pancreas at laparotomy in about 80% of
animals (mean diameter of the tumour was 1.4 ± 0.6cm).
Spontaneous necrosis in the centre of the largest tumours
was confined to a region <4 mm in diameter.
Fluorescencemicroscopy- studies
5-Aminolaevulinic acid (ALA) was obtained from Sigma
(UK) with a purity of 98%. Three different systemic routes
of ALA administration were used for hamster photosensitisa-
tion: (a) intravenous (i.v.), in which ALA was dissolved in
phosphate-buffered saline (PBS) at a concentration of
40 mgml1' and injected into the inferior vena cava at
laparotomy (total dose 200mgkg-'); (b) oral bolus (o.b.) in
which ALA, dissolved in I ml of PBS, was injected into the
stomach by a long, bulb-tip feeding needle (dose 400 mg
kg-'); and (c) oral fractionated (o.f.), in which the ALA was
first dissolved in 5 ml of saline and then injected in 1 ml
doses at I h intervals into the stomach by the feeding needle
(5 x 80 mgkg-'; total dose 400 mgkg-'). A higher total dose
of ALA for enteral dosages (o.b. and o.f. 400 mgkg-') than
for the i.v. route (200 mgkg-') was chosen because of likely
first-pass liver metabolism after oral administration, follow-
ing the results of Loh et al. (1993a), who showed that giving
an oral ALA dose twice that of the intravenous dose resulted
in similar fluorescence levels in the rat stomach, bladder and
colon. At 1, 2, 3, 4, 5, 6, 7, 8 or 24 h following either i.v. or
o.b. administration of ALA animals were killed and tumour
and normal pancreas removed and immediately frozen in a
bath of isopentane (BDH, UK) precooled in liquid nitrogen
and then stored in liquid nitrogen. For o.f. dosing the same
time points were used but refer to the time elapsed after the
first fractioned dose, and the first animals were not killed for
4 h. i.e. just after the last dose was given. Fluorescence
microscopy studies as described in detail elsewhere (Bedwell
et al., 1992) were performed on 10-pm-thick frozen sections
cut with a Cryocut E microtome (Reichert). An inverted
microscope (IMT-2, Olympus) with epifluorescence and
phase-contrast attachments and with a slow-scan, cooled,
charged-coupled device (CCD) camera (Wright Instruments)
was used to obtain fluorescence images of the selected area of
the section. A 10 x objective was used throughout to give
images of 880x 550 Lm dimensions. Fluorescence was
excited using an 8 mW helium neon laser (632.8 nm
wavelength) and detected in the range 660-710 nm using a
combination of bandpass (Omega Optical) and longpass (Schott RG655) filters. The fluorescence signal was processed by an IBM computer generating false colour-coded images. Digital quantification of the fluorescence intensity from the
areas of interest was measured in arbitrary units of counts
per pixel. This combination of laser-induced fluorescence and
the slow-scan CCD imaging technique has proven to be
sufficiently highly sensitive and reproducible for microscopic
pharmacokinetic studies (Bedwell et al., 1992). Previous
experiments correlating emission spectroscopy of ex vivo tis-
sue specimens and high-performance liquid chromatographic
(HPLC) analysis of chemically extracted prophyrins from rat
tissues (Loh et al., 1993a,b) have shown that PPIX is the
predominant (>95%) porphynrn present after ALA adminis-
tration. After fluorescence images were recorded, the same
sections were fixed in formalin and stained with haematox-
ylin and eosin for comparative light microscopy analysis,
which allowed precise identification of the fluorescing struc-
tures. Control, unsensitised tissues were also examined to
quantify the autofluorescence intensity levels.
Photodynamic therapy-short - term stud)
To assess whether ALA administration followed by laser
light illumination can induce necrosis and, if so, what is the
extent of this necrosis in our pancreatic tumour model, we
initially performed a short-term study. Pancreatic tumours in
13 animals were treated with the laser light at laparotomy 21
( 1 I) days after implantation of PC-I cells, when the mean
tumour diameter was about 1.4 cm. Since the highest
fluorescence levels in the tumours were seen 4 h after i.v.
administration and 5 h after the fractionated dosage (o.f.),
these were the time points chosen for the laser irradiation
when resultant tumour damage was likely to be maximal,
although not corresponding to the best ratio between tumour
and normal pancreas. Oral bolus dosage (o.b.) was not used
since on the basis of the fluorescence microscopy studies o.b.
ALA administration gave the weakest peak PPIX fluor-
escence. The light source was a copper vapour pumped-dye
laser (Oxford Lasers) set to deliver red light at 630 nm. There
were two main methods of light delivery. In method 1, the
laser light was coupled to a 200 Lm bare fibre which was just
touching the surface of the tumour to deliver the chosen
energy of 50J (50mW for 1,000 s); in method 2 we used a
400 gAm microlens fibre mounted inside a light-integrating
cylinder with a reflective inner surface (2.5 cm long, fibre
position 2 cm above the area to be irradiated), which enabled
more selective tumour illumination with a surface irradiance
of 50 J cm-2 (100 mW cm-2 for 500 s). Animals were killed 3,
5, 6 or 7 days later and, at autopsy, damage to the tumour
and surrounding normal tissues was assessed macroscopically
and relevant samples collected for histological analysis.
Survival study
Twenty hamsters weighing 110 g (± 10g) were injected with
PC-I cells as described above with the intention of perform-
ing a control laparotomy for tumour assessment 3 weeks
later. One animal had to be killed the day after PC-I injec-
tion because of an incisional hernia. Of the remaining 19
animals, control laparotomy performed 20-22 days after
tumour implantation revealed that four had no tumour and
that two had developed liver metastases and so these six
animals were excluded from the survival study. All animals,
including those from the control group, received the first oral
fractionated dose of ALA 5 h before laparotomy and ran-
domisation. Only animals with suitable tumours were ran-
domised. Hence, 13 tumour-bearing hamsters were ran-
domised to either the treatment or control group according
to our code, allowing for about twice as many animals in the
active treatment group. As a result of randomisation, nine
hamsters with a mean ( standard deviation) tumour
diameter of 1.4 (± 0.6 cm) underwent treatment with irradia-
tion method 2 described above, and four hamsters with a
mean tumour diameter of 1.3 ± 0.5 cm formed the control,
untreated group. The tumour diameters in the two groups
did not differ statistically (Mann-Whitney U-test, P = 0.81).
Method 2 was chosen for light exposure because we thought
that shielding of the normal tissues was desirable in the
long-term survival study. The oral fractionated dosage was
chosen because the intravenous method required two250 J. REGULA et al.
laparotomies on the treatment day and the oral bolus dose
gave weaker fluorescence in the tumour than the fractionated
one. After laparotomy and wound repair, animals were
allowed to recover and then observed every 2 days. Survival
time was defined as the time from the control laparotomy
(with or without laser treatment) to death. All animals
underwent necropsy examination. Six hamsters from the
treated group and two from the control group were killed
when they became distressed because of carcinomatosas (res-
piratory failure with ascites). Care was taken to apply the
same criteria of distress in all aimals. These studies were
carried out in accordance with procedures approved by the
Home Office.
Statistical analysis
Fluorescence intensity at a given time point was expressed as
a mean of measurements obtained from 2-4 animals after
subtracting autofluoescence intensity obtained from the
same tissues in non-sensitised animals. Each animal had
fluorescene measured in the tumour and normal pancreas at
two sites in at least two frozen sections. For survival analysis
Kaplan-Meier curves were created and survival probabilities
compared with the log-rank test. A difference was considered
to be significant at a P-value less than 0.05.
Resus
Fluorescence microscopy
Low fluorescence intensity levels not exceeding 20 counts per
pixel at any time point were detected in the normal pancreas
regardless of the route of ALA administration (Figure 1).
The highest values were obtained in the pancreatic tumour
after intravenous administration of ALA with a peak of 97
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counts per pixel at 4 h. The peak time point was similar for
an oral bolus dose (at 4 h), but the fluorescence intensity was
only half the level of that after i.v., despite the higher dose
given. Oral fractionated dosage gave fluorescence levels lower
than after i.v. but higher than after o.b. administration. Peak
values were detected at 5 h after the first dose, i.e. 1 h after
the last fractionated dose. An example of a fluorescence
image from tumour and adjacent normal pancreas at the 5 h
time-point is shown in Figure 2, which demonstrates the
marked tumour selectivity in fluorescence levels. Table I gives
the values and times of maximum tumour fluorescence for
each administration route together with the corresponding
fluorescence ratio between tumour and normal pancreas.
Photodynamic therapy-short - term results
The earliest results were obtained 3 days and the latest 7 days
after treatment. In all treated tumours (n = 13) necrosis was
evident, and the largst necrotic area had a diameter of
0.8 cm. Progression of the necrotic changes could be seen on
serial slides obtained on days 3, 5, 6 and 7. On day 3 the
'skeleton of the tumour' (i.e. damaged but recognisable his-
tological structure of the tumour) could still be seen, but on
day 7 mostly just amorphous necrotic material was present.
Smaller tumours showed complete necrosis of the entire
lesion, but larger ones usually had a rim of viable tumour on
the side opposite the irradiated surface (Figure 3). The dis-
tance from the irradiated surface of the tumour to the viable
tdmour rim was up to 0.8 cm. The border between necrosed
and viable tumour was uneven and had a tendency to follow
a
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Fiwe I Microscopic fluorescence intensity in pancreatic
tumour a, and normal pancreas b, after i.v. (0, 200mg kg-'),
o.f. (*, 400 mg kg-') and o.b. (U, 400 mg kg- ) ALA as a
function of time after administration. At 24 h after ALA,
fluorescence intensities returned to background values in all tis-
sues studied (not shown on graphs).
Fge 2 a, Fluoresence images of pancreatic tumour and nor-
mal pancreas 5 h after o.f. (400 mg kg-') ALA. Tbe highest
fluorescence is represented by white colour, the lowest by black,
according to the scale bar (from 35 to 128 counts per pixel) in the
upper part of the piture. b, The same section stained with
haematoxylin and eosin (T, tumour, N, normal pancreas). Scale
bar represents 80pm.
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Table I Maximum tumour microfluorimetric fluorescence levels and selectivity ratios for tumour
versus pancreas with intravenous or oral administration
Intravenous Oral bolus Oral fractionated
(200 mgkg-') (400 mgkg-') (5 x 80 mgkg-')
Time of maximum tumour fluorescence (h) 4 4 5'
Tumour/counts (±s.d.) 97 (11) 42 (15) 65 (15)
Pancreas/counts (±s.d.) 18 (4) 16 (5) 10 (3)
Fluorescence ratio (tumour pancreas) 5:1 3:1 6:1
aFor fractionated oral administration this time represents 5 h after the first fractionated dose.
Fugue 3 Histological section of pancreatic tumour treated with
50 J cm'2 5 h after oral fractionated 400 mg kg-' ALA showing
necrotic tumour area (NT) and the rim of viable tumour (VT) at
the opposite side to illuminated surface. Scale bar represents
I mm.
the lobular structure of the tumour delineated by thin con-
nective tissue 'strips' (Figure 4), which may be related to the
vascular supply to the different parts of the tumour or to the
protective role of connective tissue strips. The extent of the
tumour necrosis did not depend on the method of irradiation
and was similar for methods I and 2.
Normal pancreatic tissue present at the borders of the
tumour and surrounding it in most of the sections was not
damaged. However, usually small areas of pancreatic oedema
or even necrosis could be detected, but only in places where
direct irradiation took place. Control animals with untreated
tumour killed 28 days after tumour implantation (similar
time of observation as the longest observation period in the
treated group, namely 7 days after treatment) exhibited only
small areas of spontaneous tumour necrosis located in the
middle part of the tumour, which was in marked contrast to
the location of the PDT necrosis, which extended from the
borders of the tumour.
Survival study
The mean survival time of control untreated animals was 42
days (range 29-51). Animals treated with PDT after an oral
fractionated dose of ALA (400 mgkg-') irradiated at 5 h
with the cylindnrcal applicator (50 J cm-2) survived
significantly longer according to the Kaplan-Meier analysis
of survival curves (log-rank test; x = 5.86, P<0.02) (Figure
5). In all controls and six of the treated animals death was
caused by abdominal carcinomatosis with ascites. Two
treated animals died as a result of duodenal infiltration and
malnutrition: no distant metastases could be detected on
autopsy. The remaining hamster from the treated group lived
up to 116 days in apparently good health without symptoms
(to become a censored observation in the Kaplan-Meier
analysis) and was killed. On autopsy there was a 2 cm panc-
reatic tumour infiltrating liver and duodenum and slight
ascites. No damage to the surrounding normal tissues that
could be related to laser treatment was noticed in any of the
Fugwe 4 Histological section of pancreatic tumour treated with
50 J from bare fibre 4 h after i.v. 200mg kg-' ALA showing that
the borders between necrotic tumour (NT) and viable tumour
(VT) follow the lobular structure of the tumour. Scale bar
represents 1 mm.
animals from the treated group. In particular, there was no
evidence that laser treatment had caused any stenosis or
perforation of the stomach, duodenum or biliary tree.
There are only three published studies addressing PDT treat-
ment of experimental pancreatic cancer. However, the
methods used to induce the tumour in these studies were
different from our model. In the first study two models were
employed (Mang & Wieman, 1987). One was a rat pancreatic
carcinoma originally induced by azaserine and subsequently
maintained by serial transplantation into the same strains of
rat subcutaneously and intraperitoneally, which resulted in
growth of acinar cell-type carcinomas. In the second model a
pancreatic ductal-type adenocarcinoma was induced in hams-
ters by N-nitrosobis(2-oxopropyl)amine (BOP) injections and
serial subcutaneous and intrapancreatic transplantations. In
the two other studies (Schroeder et al., 1988; Chatlani et al.,
1992) Syrian golden hamsters were injected subcutaneously
with BOP to induce pancreatic ductal carcinomas. Our
method was described by Egami et al. (1989) and is based on
intrapancreatic injection of cells from the pancreatic car-
cinoma cell line (PC-1), which was originally derived from a
BOP-induced cancer in Syrian golden hamsters. This method
is relatively easy, requires less time for tumour induction and
significantly limits the use of potentially hazardous car-
cinogens. It has been shown (Takiyama et al., 1990) that this
model shares many characteristics with human disease.
In two of the cited studies (Mang & Wieman, 1987;
Schroeder et al., 1988) Photofrin was used as the photosen-
sitising agent, whilst Chatlani et al. (1992) studied aluminium
sulphonated phthalocyanine (AlSPc). The alluring feature of
5-aminolaevulinic acid (ALA)-induced PPIX sensitisation, as
used in this study, is- the significantly decreased risk of pro-
longed skin photosensitivity. ALA can also be administered
orally, as has been reported in human subjects, but only as a252 J. REGULA et al.
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Fuge 5 Kaplan-Meier survival curves for Syrian golden hams-
ters with transplanted pancreatic tumours companing the PDT-
treated group (-= 9) with the control, non-treated group (0,
n=4) (log-rank test, P<0.02).
single bolus dose (Berlin et al., 1956; Grant et al., 1993; Loh
et al., 1993a). We have compared two methods of oral ALA
administration (bolus and fractionated). We anticipated that
oral fractionated doses would result in better tissue uptake
than an oral bolus because ALA and its metabolite, por-
phobilinogen, are very quickly excreted in the urine after a
bolus dose (Berlin et al., 1956). The peak plasma concentra-
tion of ALA in humans after a single dose is reached at
60 min and the half-life (t,2) of its clearance from the circula-
tion is only about 50 min (Mustajoki et al., 1992), so fre-
quent repeated doses should maintain a steady, high blood
level of ALA for a longer time. A similar approach was
adopted in another recent study in which prolonged adminis-
tration of ALA to rats over 11 days (in drinking water)
resulted in a betterliver tumour/normal liver PPIX ratio than
shorter periods of administration (van Hillegersberg et al.,
1992). This tendency for better tumour uptake of ALA and
accumulation of PPIX after fractionated as opposed to bolus
dosing was confirmed in the present study. Another potential
advantage of fractionating the ALA dose is that any asyn-
chrony in PPIX synthesis among the malignant cells may be
minimised. However, in this work the best results in terms of
the efficiency of PPIX conversion from ALA were obtained
after intravenous injection, as found previously in studies of
normal rat stomach and colon (Loh et al., 1993a). ALA
arriving from the portal circulation after an oral dose can be
quickly metabolised to porphyrins by hepatocytes in situ and
then excreted into the bile and thus lost to the systemic
circulation.
Recent studies of animal tissues after systemic ALA
administration using chemical extraction have shown that the
porphyrin content is at least 95% protoporphyrin IX (Loh et
al., 1993b). Good correlation was also found between
chemically extracted levels of PPIX and microfluorimetric
measurements using our technique in tissue layers of the
gastrointestinal tract (Loh et al., 1993b). In rat gastric and
colonic mucosa, and in a duodenal tumour model, a
fluorescence intensity of 100 counts per pixel (recorded with
the 10 x objective to give the same calibrated sensitivity as
the present work) was found to correspond to approximately
5-6 jig of PPIX per gram of tissue. Assuming that similar
PPIX fluorescence efficiencies apply to the pancreatic tumour
model, we would estimate PPIX levels of about 5 ;.g g ' 4 h
after 200 mg kg-' i.v. administration. Despite the lack of
absolute determination of PPIX levels, there are several
advantages of the microfluorimetric technique compared with
chemical extraction: firstly, we can monitor changes in the
microscopic PPIX distribution which would not have been
apparent from the gross extraction technique; and, secondly,
using an H&E-stained serial section, it is easier with the
microscopic technique to discriminate between viable and
necrotic tumour. This is important, since PPIX is not syn-
thesized in necrotic regions and with an extraction technique
it is sometimes difficult to exclude sampling of necrotic areas.
Normal pancreatic tissue showed relatively low fluorescence,
regardless of the route of ALA administration, and much
lower than other normal tissues (stomach. colon, bladder)
studied by Loh et al. (1993a). The ratio between tumour and
normal pancreatic tissue fluorescence levels in our study
varied at different time points beween 1:1 and 8:1. For
intravenous and oral (fractionated) administration the selec-
tivity ratio between tumour and pancreas at the time of
maximum tumour fluorescence was 5-6:1, although with
oral (bolus) administration this ratio was lower at 3:1. How-
ever Mang and Wieman (1987) found no difference in
Photofrin concentrations 24 h after injection between int-
rapancreatic tumours and normal pancreas in their rat and
hamster models. In the study of Schroeder et al. (1988) the
activity of'"I-labelled Photofrin was studied 3 and 48 h after
administration and was almost twice as high in the panc-
reatic tumour as in the normal pancreas at both time points.
In the case of aluminium sulphonated phthalocyanine (a
mixture containing mono- to tetrasulphonates with the mean
corresponding to trisulphonated) at the optimum time (48 h),
the chemically extracted concentration (as measured using
fluorescence detection) was about three times higher in the
pancreatic tumours as in the normal pancreas (Chatlani et
al., 1992). Hence, using ALA-induced PPIX sensitisation the
tumour to normal ratios demonstrate better selectivity than
found with conventional exogenous sensitisation. Good selec-
tivity has also been found in large bowel and experimental
mammary carcinomas with this method of sensitisation
(Bedwell et al., 1992; Peng et al., 1992). One of the possible
explanations for this selective tumour accumulation of PPIX
could be lower ferrochelatase activity in the tumour cells
compared with normal tissues, as shown by van Hillegersberg
(1992) and Schoenfeld et al. (1988) in combination with
higher levels of porphobilinogen deaminase in tumour (Bat-
lIe. 1993). However, the selectivity found here is exceptional
and must partly be explained by the relatively low PPIX
fluorescence levels found in normal pancreas, which may also
be a consequence of low activities of certain haem enzymes in
this organ. On reaching maximum fluorescence levels in the
pancreas, the PPIX appears to be associated with intercel-
lular regions corresponding to the capillary and lymphatic
network. A similar fluorescence pattern has been noted for
the porphyrins and phthalocyanines (Nuutinen et al., 1991).
Further work with confocal imaging to give higher resolution
would be desirable and might help to explain the resistance
of normal pancreas to PDT damage, which appears to be a
general phenomenon applying to all sensitisers studied thus
far. When the same light dose was applied to the tumours
and normal pancreas in the experiments of Mang and
Wieman (1987) (tumour and normal pancreas had identical
Photofrin concentrations), the damage was limited to tumour
only. This phenomenon was accompanied by a notable lack
of photobleaching of the Photofrin in normal tissues as
compared with photobleaching in the tumour. It was sug-
gested that normal pancreas contains high amounts of singlet
oxygen scavengers which could maintain sublethal levels of
singlet oxygen and also inhibit singlet oxygen-induced
photodegradation. Chatlani et al. (1992) reported results with
sulphonated aluminium phthalocyanine showing that the
light dose necessary to induce necrosis in tumours resulted in
no damage to normal pancreas. These authors also calculated
that the threshold photodynamic dose for damage (light dose
multiplied by concentration of photosensitiser) to normal
pancreas was about seven times as high as for damage to
pancreatic tumour. Studies trying to explain this pheno-
menon have been undertaken but are inconclusive (Matthew
& Cui, 1990; Moesta et al., 1992). Studies of photobleaching
of ALA-induced PPIX and phthalocyanine in pancreas
would provide a useful comparison with those performed
with Photofrin. On the other hand, serious pancreatic
damage was induced in another study (Schroder et al., 1988)
in which irradiation of the tumour was performed from a
distance of about 3-4 cm, and most probably larger areas of
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This caused necrotising pancreatitis and death in one of
seven animals. Another three animals also died from gastro-
duodenal perforations. The irradiation techniques described
in the present study limited exposure to the pancreatic
tumour and small areas of adjacent normal pancreas. Using
this method only small areas of damage to the normal pan-
creas could be seen on histological examination, and these
were at the places directly exposed to laser light. One cannot
exclude the possibility that this was a result of thermal
damage, which all PDT studies try to exclude. Many
previous studies have reported small areas of damage where
the fibre touches the target - so-called thermal controls
(exposed to laser without previous sensitiser administration)
(Barr et al., 1987; Chatlani et al., 1992).
The maximum depth of necrosis induced in the tumours by
PDT in our study was 8 mm, with a viable rim of
undamaged tumour tissue at the side opposite the irradiated
area. Borders between necrotic areas and viable tumour
appeared to follow the lobular structure of the tumour. This
may be related to the vascular supply pattern of the tumour
or perhaps the protective role of connective tissue strips
dividing tumour into lobules. Of the three experimental pan-
creatic tumour PDT studies, only Chatlani et al. (1992) give a
description of the localisation of the necrosis within the
tumour. Their description is quite similar to our findings.
They also reported a maximum of 8 mm necrosis of the
tumour and a viable rim at the areas furthest from the site of
light application. One can argue that the presence of a viable
tumour rim should be considered an unsatisfactory result,
but it is well established that light penetration is a limiting
factor of PDT. If surface illumination, as used in our study,
can produce damage up to 8 mm, this would be sufficient if
PDT followed other tumour volume-reducing procedures
such as surgery, and in these circumstances PDT would only
aim at 'sterilising' resection margins. Other possibilities can
also be considered, such as multiple fibres inserted at
different depths into the tumour tissue to illuminate larger
volumes.
No other studies have presented survival analysis after
PDT for pancreatic tumours. This study shows favourable
results, with significant prolongation of survival after treat-
ment. However, all animals had a tumour recurrence, most
probably from the rims of viable tumour observed in our
short-term study or from incompletely destroyed microscopic
foci of tumour.
In summary, the results of this study suggest that pan-
creatic tumours up to 8 mm in depth can be destroyed fol-
lowing ALA administration and application of 50 J cm-2 of
630 nm laser light. Partial destruction of the tumour results
in a prolongation of survival of experimental animals. These
data would justify further studies of PDT for pancreatic
cancer, which should also consider how pancreatic tumours
could be treated in clinical practice. Imaging of pancreatic
lesions is difficult and leads to delays in diagnosis and treat-
ment. Therefore the most probable application of PDT in
this disease would be as an adjunct to surgery. In this
situation destruction of tumour to a depth of up to 8 mm, as
found here, can be sufficient to destroy micrometastases in
the operative area, and for small tumours PDT could be used
as the primary treatment. Intraoperative PDT is already
being seriously considered (DeLaney et al., 1993; Evrad et
al., 1993) and hopefully will become established in the future
treatment of intra-abdominal malignancy.
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